Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia

Acute myeloid leukemia (AML) is a blood cancer that is poorly responsive to conventional cytotoxic chemotherapy and a diagnosis of AML is usually fatal. More effective and better-tolerated therapies for AML are desperately needed. Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are one of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Exp Hematol
Asıl Yazarlar: Gregory, Mark A., Nemkov, Travis, Reisz, Julie A., Zaberezhnyy, Vadym, Hansen, Kirk C., D’Alessandro, Angelo, DeGregori, James
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815916/
https://ncbi.nlm.nih.gov/pubmed/28947392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.exphem.2017.09.007
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller